357 related articles for article (PubMed ID: 20510761)
1. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review.
Shuja F; Chan CS; Rosen T
Dermatol Clin; 2010 Jul; 28(3):511-21, 523-4; quiz 522-3. PubMed ID: 20510761
[TBL] [Abstract][Full Text] [Related]
2. The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review.
van Rappard DC; Limpens J; Mekkes JR
J Dermatolog Treat; 2013 Oct; 24(5):392-404. PubMed ID: 22397574
[TBL] [Abstract][Full Text] [Related]
3. Management of hidradenitis suppurativa with biological therapy: report of four cases and review of the literature.
Bahillo Monné C; Honorato Guerra S; Schoendorff Ortega C; Gargallo Quintero AB
Dermatology; 2014; 229(4):279-87. PubMed ID: 25472035
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept.
Poulin Y
J Cutan Med Surg; 2009; 13(4):221-5. PubMed ID: 19706231
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging nonsurgical treatment options for hidradenitis suppurativa.
Kerdel FA
Semin Cutan Med Surg; 2014 Jun; 33(3 Suppl):S57-9. PubMed ID: 25188460
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.
Haslund P; Lee RA; Jemec GB
Acta Derm Venereol; 2009 Nov; 89(6):595-600. PubMed ID: 19997689
[TBL] [Abstract][Full Text] [Related]
7. Use of biological treatments in patients with hidradenitis suppurativa.
Martin-Ezquerra G; Masferrer E; Masferrer-Niubò M; Ferran M; Sánchez-Regaña M; Collgros H; Bordas X; Notario J; Alsina M; Gil I; Izquierdo N; Aparicio G; Mollet J; Garcia-Patos V; Pujol RM
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):56-60. PubMed ID: 24629001
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Weinberg JM; Saini R; Tutrone WD
J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
[TBL] [Abstract][Full Text] [Related]
9. Moderate to severe hidradenitis suppurativa treated with biological therapies.
Chinniah N; Cains GD
Australas J Dermatol; 2014 May; 55(2):128-31. PubMed ID: 24456051
[TBL] [Abstract][Full Text] [Related]
10. Etanercept: effective in the management of hidradenitis suppurativa.
Cusack C; Buckley C
Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial.
Pelekanou A; Kanni T; Savva A; Mouktaroudi M; Raftogiannis M; Kotsaki A; Giamarellos-Bourboulis EJ
Exp Dermatol; 2010 Jun; 19(6):538-40. PubMed ID: 19758320
[TBL] [Abstract][Full Text] [Related]
13. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
[TBL] [Abstract][Full Text] [Related]
14. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
15. Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept.
Henderson RL
J Drugs Dermatol; 2006; 5(10):1010-1. PubMed ID: 17373153
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapy of psoriatic arthritis.
Gladman DD
Reumatismo; 2007; 59 Suppl 1():85-7. PubMed ID: 17828353
[TBL] [Abstract][Full Text] [Related]
17. [Biologics in the treatment of psoriasis].
Dissemond J; Grabbe S
MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
Trent JT; Kerdel FA
Dermatol Nurs; 2005 Apr; 17(2):97-107. PubMed ID: 15916184
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
Brunasso AM; Puntoni M; Salvini C; Delfino C; Curcic P; Gulia A; Massone C
Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813
[TBL] [Abstract][Full Text] [Related]
20. [Novel biologics in treatment of psoriatic arthritis].
ZHOU J; ZHENG M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):404-8. PubMed ID: 19693980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
